TITLE:
CDX2 Overexpression in Barrett’s Esophagus and Esophageal Adenocarcinoma
AUTHORS:
Leandro Almeida Streher, Vinicius Campos, Guilherme da Silva Mazzini, Marcelo Binato, Luise Meurer, Maria Isabel Edelweiss, Richard Ricachenevsky Gurski
KEYWORDS:
CDX2, Barrett’s Esophagus, Intestinal Metaplasia, Esophageal Adenocarcinoma, Immunohistochemistry
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.5 No.7,
June
3,
2014
ABSTRACT: Background: Patients with Barrett’s esophagus have an increased risk of
developing esophageal adenocarcinoma. Our purpose was to determine CDX2
expression in esophageal mucosa and establish a correlation between this marker
and the progression of disease. Methods: We analyzed biopsies and surgical
specimens from 150 patients who were divided into five groups according to
histopathological diagnosis: G1, normal mucosa (n = 29); G2, esophagitis (n = 19); G3, columnar epithelium without intestinal metaplasia (n = 26); G4, Barrett’s esophagus (n = 32), and G5, adenocarcinoma (n = 44). Immuno-histochemical
determination of CDX2 expression was considered positive in the presence of
nuclear staining. Results: No CDX2 expression was detected in the G1 or G3
groups; 5% of G2, 62.5% of G4 and 70.5% of G5 patients were CDX2 positive.
There was a statistically significant difference between the G4 and G5 groups
compared to the G1, G2 and G3 (p